Collegium Pharmaceutical (COLL) Restructuring Costs (2021 - 2025)

Collegium Pharmaceutical's Restructuring Costs history runs 3 years deep, the most recent figure standing at $10.9 million for Q3 2025.

• On a quarterly basis, Restructuring Costs rose 39.88% year-over-year to $10.9 million in Q3 2025; TTM through Sep 2025 was $43.5 million, a 50.89% increase from a year earlier, with the FY2024 full-year figure at $33.7 million, up 4.27% from the prior year.
• Restructuring Costs grew to $10.9 million in Q3 2025 per COLL's latest filing, from $9.8 million in the prior quarter.
• Across five years, Restructuring Costs topped out at $13.3 million in Q1 2025 and bottomed at $4.6 million in Q4 2021.
• The 3-year median for Restructuring Costs is $9.0 million (2024), against an average of $9.0 million.
• Biggest YoY gain for Restructuring Costs was 54.11% in 2025; the steepest drop was 25.49% in 2025.
• Year by year, Restructuring Costs stood at $4.6 million in 2021, then surged by 106.92% to $9.5 million in 2024, then climbed by 15.12% to $10.9 million in 2025.
• Per Business Quant, the three latest COLL Restructuring Costs figures stand at $10.9 million (Q3 2025), $9.8 million (Q2 2025), and $13.3 million (Q1 2025).